Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

The strategy tethers IL-12 to a PD-L1 blocker to concentrate immune activation at the tumor with minimal systemic toxicity.